Janux Therapeutics, Inc.

Historical 13F Holders

Symbol
JANX
CUSIP
47103J105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 47103J105 since 12/18/2024, largest first.

Filer % of Class Filed
RA Capital Management, L.P. 13D/A
19.9% 3/10/2025
Event 3/6/2025
BlackRock, Inc. 13G/A 6.7% 7/28/2026
Event 6/30/2026
Prosight Management, LP 13G
5.3% 2/6/2026
Event 2/3/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Paradigm Biocapital Advisors LP 13G/A
4.9% 8/14/2025
Event 6/30/2025
Adage Capital Management, L.P. 13G/A
4.3% 8/12/2025
Event 6/30/2025
FMR LLC 13G/A
4.2% 5/6/2026
Event 3/31/2026
State Street Corp 13G 4.1% 5/12/2026
Event 3/31/2026
Point72 Asset Management, L.P. 13G/A
3.3% 8/14/2026
Event 6/30/2026
Janus Henderson Group Ltd. 13G/A 0.3% 8/13/2026
Event 6/30/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 90.2 k $1.56 M
2026 Q2 210 62.4 M $997 M
2026 Q1 203 59.6 M $828 M
2025 Q4 194 62.2 M $860 M
2025 Q3 186 65.4 M $1.60 B
2025 Q2 189 65.8 M $1.52 B
2025 Q1 196 66.5 M $1.81 B
2024 Q4 234 64.1 M $3.43 B
2024 Q3 171 45.6 M $2.07 B
2024 Q2 170 46.3 M $1.94 B
2024 Q1 132 43.1 M $1.62 B
2023 Q4 72 33.6 M $361 M
2023 Q3 62 35.1 M $354 M
2023 Q2 57 30.5 M $362 M
2023 Q1 51 30.5 M $370 M
2022 Q4 54 29.2 M $385 M
2022 Q3 51 31.5 M $427 M
2022 Q2 45 28.9 M $353 M
2022 Q1 48 28.4 M $407 M
2021 Q4 47 27.5 M $542 M
2021 Q3 46 26.5 M $571 M
2021 Q2 31 24.7 M $614 M